Skip to main content

Table 5 Fatigue-related treatment-emergent adverse events that occurred during the acute and extension phases

From: Improvement in multiple dimensions of fatigue in patients with fibromyalgia treated with duloxetine: secondary analysis of a randomized, placebo-controlled trial

Treatment-emergent adverse events

Acute phase

Extension phase

 

Duloxetine

(n= 263)

Placebo

(n= 267)

Duloxetine/Duloxetine (n= 176)

Placebo/Duloxetine

(n= 187)

Chronic fatigue syndrome

0

0.4

0

0

Fatigue

9.5

7.1

3.4

4.8

Insomnia

9.1

7.1

3.4

3.7

Lethargy

1.9

0.7

0

0.5

Sedation

2.3

1.1

2.3

2.1

Sluggishness

0.4

0

0

0

Somnolence

5.7

3.4

1.1

3.7

  1. Values are presented as percentages.